跳转至内容
Merck
CN
  • [Final height (FH) in Turner syndrome (TS): experience of 76 cases followed at the Pediatric Endocrinology Unit, Hospital de Clinicas, Federal University of Paraná].

[Final height (FH) in Turner syndrome (TS): experience of 76 cases followed at the Pediatric Endocrinology Unit, Hospital de Clinicas, Federal University of Paraná].

Arquivos brasileiros de endocrinologia e metabologia (2011-09-02)
Ana Vládia Ramos Fonteles, Roberta Savaris Dondoni, Margaret Cristina da Silva Boguszewski, Suzana Nesi-França, Rosana Marques-Pereira, Romolo Sandrini Neto, Luiz de Lacerda Filho
摘要

To report the final height (FH) of 76 patients with Turner syndrome (TS). Review of the files and calculation of z scores: of target height (TH), and FH according to NCHS/CDC/2000 and FH according to Lyon and cols. Patients were classified in three groups: A (n = 16), treatment with estrogens and progestogens; B (n = 21), treatment with oxandrolone (OX); C (n = 39), growth hormone (GH) plus OX. The z score of TH was not different among the groups and z score of FH was not different between A e B. Z score of FH of group C was greater than the other groups, > 2SDS of Lyon's curve and fitted on the 3(rd) percentile of NCHS/CDC. Multiple regression analysis showed type of treatment (p < 0.001) and maternal height (p = 0.02) as most influencing factors on FH. GH plus OX and maternal height contributed significantly to enhance FH of TS patients.